MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Diagnosis & Differentiation

Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

European Radiology 2019 January 28 [Link] Halpenny D, Raj M, Rimner A, Zheng J, Capanu M, Ginsberg MS Abstract OBJECTIVE: This study was conducted in order to describe the computed tomography (CT) features of local pleural recurrence in patients with malignant pleural mesothelioma undergoing intensity-modulated pleural radiation therapy (IMPRINT) as part of multimodality treatment. METHODS: […]

Comments Off on Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Biochemical and Biophysical Research Communications 2019 March 5 [Link] Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE Abstract Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the […]

Comments Off on Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Applied Immunohistochemistry & Molecular Morphology 2019 January 11 [Link] Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A Abstract Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss […]

Comments Off on BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Lung Cancer 2019 January [Link] Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, Borg E, Falzon M, Nankivell M, Nicholson AG, Janes SM Abstract Introduction BRCA1 associated protein-1 (BAP1) is a key tumor driver in mesothelioma and a potential biomarker predicting response to several targeted therapies in clinical testing. Whether it also modulates response to cytotoxic chemotherapy is undetermined. This study used […]

Comments Off on Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Lung Cancer 2019 January [Link] Chapel DB, Churg A, Santoni-Rugiu , Tsujimura T4, Hiroshima K5, Husain AN Abstract The pathologist plays a central role in the diagnosis and management of malignant mesothelioma, including definitive tissue-based diagnosis in conjunction with clinical and radiographic data; diverse ancillary studies of diagnostic, prognostic, and predictive importance; and research efforts to better define the pathobiology of […]

Comments Off on Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Heparanase inhibitors restrain mesothelioma.

Oncotarget 2018 December 7 [Link] Lapidot M1, Barash U1, Vlodavsky I1, Pass H2. Abstract Malignant mesothelioma is a highly aggressive form of cancer with poor prognosis due to lack of markers for early diagnosis and resistance to conventional therapies. Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this […]

Comments Off on Heparanase inhibitors restrain mesothelioma.

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.

Frontiers in Oncology 2018 December 21 [Link] Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a variable incidence among different countries. Occupational asbestos exposure is the most important etiological factor and a very long latency […]

Comments Off on MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.

Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.

European Radiology 2019 January 7 [Link] Li F, Ahmad M, Qayyum F, Straus CM, MacMahon H, Kindler H, Armato SG Abstract OBJECTIVES: To evaluate differences in the tumor response classifications that result from clinical measurements and to compare these response classifications with overall survival for patients with malignant pleural mesothelioma (MPM). METHODS: One hundred thirty-one […]

Comments Off on Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.

Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event.

International Journal of Molecular Sciences 2019 January 3 [Link] Turini S, Bergandi L, Gazzano E, Prato M, Aldieri E Abstract Asbestos exposure increases the risk of asbestosis and malignant mesothelioma (MM). Both fibrosis and cancer have been correlated with the Epithelial to Mesenchymal Transition (EMT)-an event involved in fibrotic development and cancer progression. During EMT, […]

Comments Off on Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

EBioMedicine 2018 December 20 [Link] Sciarrillo R1, Wojtuszkiewicz A2, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E Abstract INTRODUCTION: Therapeutic options for diffuse malignant peritoneal […]

Comments Off on Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.